Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251938 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
A Phase 3 study of Non-Infectious Uveitis of the Posterior Segment of the Eye, sponsored by Santen.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT02251938 is a Phase 3 study of Non-Infectious Uveitis of the Posterior Segment of the Eye that has completed, run by Santen. The registered enrollment target is 60 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT02251938, a Phase 3 study of Non-Infectious Uveitis of the Posterior Segment of the Eye, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program.
Conditions Studied
Interventions
- DRUG DE-109 440 μg
Study Locations (20)
New Jersey
- - New Brunswick
- - Palisades Park
New York
- - New York
- - Orchard Park
Other
- - Graz
- - Paris
New Dehli
- - Aurobindo Marg
- - Daryāganj
Arizona
- - Phoenix
California
- - Sacramento
Colorado
- - Golden
Florida
- - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2017-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251938
The ClinicalTrials.gov registry entry for NCT02251938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Infectious Uveitis of the Posterior Segment of the Eye appearing as the primary indexed condition, and to 1 intervention - of which DE-109 440 μg is the first listed.
NCT02251938 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New Jersey, New York, Other.
Frequently Asked Questions
What is clinical trial NCT02251938 about?
NCT02251938 is a clinical study titled "A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program". The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA development program.
What is the current status of trial NCT02251938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2014-09-29. Estimated completion is 2017-11-27.
What conditions does trial NCT02251938 study?
This clinical trial studies the following conditions: Non-Infectious Uveitis of the Posterior Segment of the Eye.
What interventions are being tested in trial NCT02251938?
The interventions under investigation include: DE-109 440 μg (DRUG).
Who is sponsoring clinical trial NCT02251938?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02251938 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.